|
|
||||||||||
|
J Am Coll Cardiol, 2005; 46:1076-1084, doi:10.1016/j.jacc.2005.05.073
(Published online 7 September 2005). © 2005 by the American College of Cardiology Foundation |





* Institute of Cardiology, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy
Nuclear Medicine Unit, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy
Department of Pathology, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy
Department of Neurology, Ospedale Bellaria, Bologna, Italy.
Manuscript received March 4, 2005; revised manuscript received May 18, 2005, accepted May 24, 2005.
* Reprint requests and correspondence: Prof. Claudio Rapezzi, Istituto di Cardiologia, Policlinico S. Orsola-Malpighi, via Massarenti 9, 40138 Bologna, Italy. (Email: crapezzi{at}aosp.bo.it).
OBJECTIVES: We investigated the diagnostic accuracy of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy for differentiation of monoclonal immunoglobulin light-chain (AL) and transthyretin (TTR)-related cardiac amyloidosis.
BACKGROUND: Differential diagnosis between TTR-related and AL amyloidosis is often complex and time-consuming.
METHODS: Patients under routine observation with TTR-related/AL systemic amyloidosis and echocardiographic evidence of cardiac involvement were studied with 99mTc-DPD scintigraphy.
RESULTS: Patients with cardiac involvement of TTR-related (group A; n = 15) and AL (group B; n = 10) etiology were comparable for left ventricular mass and renal function. Heart and heart/whole-body tracer retention were significantly higher (p < 0.05) in group A as compared with group B and with 10 unaffected controls. At visual scoring, cardiac 99mTc-DPD uptake was present in all group A patients and absent in all group B patients; thus, using genotyping/immunohistochemistry as the reference technique, the accuracy of 99mTc-DPD scintigraphy for distinction of TTR-related and AL etiology was 100%. Cardiac 99mTc-DPD uptake was also absent among unaffected controls. Using echocardiography as the reference standard for recognition of cardiac involvement, sensitivity and specificity of scintigraphy were both 100% for group A patients; in group B, sensitivity was 0% and specificity was 100% (accuracy, 50%). Eleven patients with myocardial 99mTc-DPD uptake underwent 99mTc-methylene diphosphonate (99mTc-MDP) scintigraphy; all patients showed a 99mTc-MDP myocardial visual score of 0.
CONCLUSIONS: Etiology is a third major causein addition to type of organ-involved (soft-tissue/heart) and tracer typeof scintigraphic variability in cardiac amyloidosis. This is a highly relevant consideration for future studies. We conclude that 99mTc-DPD scintigraphy is a useful step in the workup of the differential diagnosis of TTR versus AL etiology in patients with documented cardiac amyloidosis.
| |||||||||||
This article has been cited by other articles:
![]() |
C. Rapezzi, P. Guidalotti, F. Salvi, L. Riva, and E. Perugini Usefulness of 99mTc-DPD Scintigraphy in Cardiac Amyloidosis J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1509 - 1510. [Full Text] [PDF] |
||||
![]() |
J. B. Selvanayagam, P. N. Hawkins, and S. Neubauer Reply J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1510 - 1510. [Full Text] [PDF] |
||||
![]() |
K. B. Shah, Y. Inoue, and M. R. Mehra Amyloidosis and the heart: a comprehensive review. Arch Intern Med, September 25, 2006; 166(17): 1805 - 1813. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |